Is EBO2 (EBOO) FDA Approved? Ozone Therapy's Legal Status Explained

EBO2 (also called EBOO) is one of several names clinics use for extracorporeal blood oxygenation and ozonation; a fuller description of the procedure itself is in the pillar guide on what EBO2 is. This guide answers a narrower question: whether any government agency, in the United States or elsewhere, has approved it.

The short answer

No. EBO2 is not FDA-approved, and neither is any other form of ozone therapy; federal regulation describes ozone itself as a toxic gas with no known useful medical application. Clinics can still legally offer it because state law, not FDA approval, governs the practice of medicine, and no other country’s medicines regulator has approved it either. The rest of this guide walks through the specific regulation, the warning letters clinics have received, and what state and other countries actually allow, since “not FDA-approved” gets misused in both directions.

What 21 CFR 801.415 says, in plain language

The regulation clinics and skeptics both point to is 21 CFR 801.415, part of the FDA’s device labeling rules. Its first paragraph states: “Ozone is a toxic gas with no known useful medical application in specific, adjunctive, or preventive therapy. In order for ozone to be effective as a germicide, it must be present in a concentration far greater than that which can be safely tolerated by man and animals” [1]. The same section lists a physiological effect of ozone as irritation of the mucous membranes and lungs, warning that inhaled ozone can cause pulmonary edema that is often delayed by hours, so that a person’s own sense of discomfort is not a reliable warning sign of dangerous exposure, and separately states that a device is considered adulterated or misbranded if it generates ozone for use “in any medical condition for which there is no proof of safety and effectiveness” [1]. The same regulation sets a maximum ozone level of 0.05 parts per million for devices used around the public, and separately notes that this does not affect a pre-existing 0.10 parts per million threshold for an eight-hour industrial workday, a limit the section attributes to the American Conference of Governmental Industrial Hygienists rather than setting itself [1]. In plain language: the FDA’s own regulation describes ozone as toxic, not therapeutic, treats any medical use claim for it as a labeling violation rather than an approved indication, and its only numeric limits concern how much ozone is safe to breathe in the air, not how much is safe or effective to add to a patient’s blood.

Devices vs practice: why clinics can offer it anyway

If ozone has no approved medical use, a reasonable question is how a clinic can legally offer EBO2 at all. The answer is that 801.415 is a device rule; it constrains how an ozone-generating device can be labeled and marketed, not what a licensed physician can do in the practice of medicine. Medicine is regulated state by state, and most states allow a licensed physician latitude to offer treatments outside FDA-approved indications, sometimes called off-label practice, as long as the physician does not make specific disease-treatment claims and obtains informed consent. One clinic FAQ makes the distinction clinics themselves rely on: the filtration devices used in EBO2 are often FDA-registered for blood processing in a general sense, but the FDA does not approve medical procedures, only drugs and devices, and it has not approved EBO2 as a treatment for any disease [2]. Another clinic FAQ states plainly that EBOO therapy itself is considered an alternative or supportive therapy and is not FDA-approved to treat specific conditions, even though the underlying filtration hardware may be FDA-registered for blood processing [3]. Being legal to offer is not the same as being approved to treat.

What FDA and FTC have done about ozone marketing

Both the FDA and the FTC have taken action against specific ozone therapy claims, most visibly during the 2020 COVID-19 pandemic. In April 2020, the FTC sent a warning letter to RowenSu Clinic in Santa Rosa, California, citing website language that marketed ozone therapy as a “Cost[] Effective Treatment for Corona Virus” and claimed the virus “may have a soft underbelly [that is] easily and safely exploitable with ozone therapy” [4]. The letter states plainly that advertising a product or service as able to treat human disease without competent and reliable scientific evidence, including well-controlled clinical studies, violates the FTC Act, and that no such study was known to exist for COVID-19 at the time [4]. In May 2020, the FDA and FTC jointly sent a warning letter to Center for New Medicine and Perfectly Healthy, run by Dr. Leigh Erin Connealy, over social media posts stating that “ozone destroys viruses” and that the clinic offered services “intended to deal exactly with situations like COVID-19,” alongside other posts promoting vitamin C, silver, and UV light as coronavirus countermeasures [5]. That letter gave the clinic 48 hours to describe the specific steps it had taken to correct the violations, and it warned that failing to do so could lead to further legal action, including seizure of products or an injunction [5]. The FDA separately maintains a public list of firms warned over fraudulent COVID-19 products, and its own case log includes a court order stopping a Dallas wellness center from touting ozone therapy as a COVID-19 treatment [6]. Other ozone-related warning letters exist beyond these two, and together they show a consistent pattern: enforcement follows specific disease-treatment claims rather than the act of offering ozone therapy itself, and a firm that receives one is expected to respond quickly and correct the claim or face escalation.

State-level oversight

State medical boards, not the FDA, are the primary check on how an individual physician uses ozone. Their responses vary. When a physician asked the Alabama State Board of Medical Examiners for permission to use ozone therapy in a pain practice in 2011, the board replied that it does not regulate specific practice procedures and declined to make a recommendation either way. It did caution the physician that, “due to the experimental and investigational nature of the non-FDA approved therapy, the Board would be extremely concerned should any patient complaints be received related to the use of Ozone therapy” [7]. That is neither an endorsement nor a ban; it is a state regulator declining to bless the practice while putting the physician on notice that complaints would draw scrutiny. Other states have handled the question differently, and a physician’s protection from discipline for using ozone therapy depends on the specific state’s medical practice act, not on any federal approval. A patient cannot assume that a clinic operating legally in one state has cleared any particular bar in another, since each state medical board sets and enforces its own standard for what counts as acceptable practice, and boards do not coordinate a single national position on ozone therapy the way the FDA sets a single national position on drug approval.

How other countries handle it

Clinics sometimes suggest that ozone therapy is officially approved elsewhere, even if not in the United States. The clearest documentation available is the Madrid Declaration on Ozone Therapy, published by ISCO3, an international association of ozone therapy practitioners. ISCO3 describes its own document as the first and only global consensus document in the history of ozone therapy, built from more than 2,000 scientific publications; the document was produced after ISCO3 solicited proposals and revisions from ozone therapy practitioners in many countries for its second edition, not signed or ratified by any government [8]. That is a practitioner association’s internal professional guidance, written by ozone therapists for ozone therapists. It is not a national medicines or device regulator approving ozone therapy the way the FDA approves a drug or clears a device, and nothing in the document functions as government marketing authorization in any country.

Looking at specific countries makes the same point more concretely, and the clearest accounts available for this guide come from AEPROMO, the Spanish association of ozone therapy practitioners, and from Cuba’s state-run press, neither of which is a neutral regulator. Germany permits ozone therapy under a general legal principle called “freedom of therapy,” which lets a doctor select an unauthorized product as treatment without the product itself being approved as a medicine. On December 11, 2020, though, Germany’s Federal Joint Committee, the public body that decides what statutory health insurance covers, formally listed ozone therapy among treatments that cannot be provided at statutory insurance expense. The committee explained that decision in a 33-page report published March 30, 2021, concluding: “The benefits, necessity and cost-effectiveness of ozone therapy have not been demonstrated” [9]. Italy has regional directives, dated 2003, 2007, and 2009, permitting ozone therapy in three of its twenty regions, and Spain has similar private-sector directives in 15 of its 17 autonomous communities issued between 2007 and 2012, plus use in a small and growing number of public hospitals; both are regional administrative allowances for licensed physicians, not a national medicines regulator approving a treatment [10]. Cuba is the clearest case of government adoption: its Ministry of Public Health supplies ozone generators to its own healthcare facilities and, according to Cuba’s state-run Granma newspaper, folded ozone therapy into its official Natural and Traditional Medicine program in 2010 [11]. Even that, the strongest example found for this guide, is a government health system choosing to run the therapy in its own facilities, reported by that same government’s press, rather than an independent regulator reviewing controlled trials and approving a specific product for a specific condition the way the FDA does.

Anyone told that ozone therapy is “approved in Europe,” “approved in Germany,” or similarly should ask specifically which government agency approved it, for which condition, and on what evidence, since a professional consensus statement, a health-insurance coverage decision, or a regional practice directive is not the same thing as a safety-and-efficacy approval. A document that practitioners write for other practitioners can still be useful as shared clinical guidance, in the same way a specialty society’s own treatment protocol can be useful without being a marketing authorization, but describing any of this to a patient as a foreign government’s approval overstates what it actually is.

What “not FDA-approved” should mean for a patient’s decision

“Not FDA-approved” does not automatically mean illegal, dangerous, or fraudulent on its own. It means no federal agency has reviewed controlled evidence and concluded that EBO2 works for a specific condition, which is a different and lower bar than clinics sometimes imply when they mention FDA-registered equipment or point to practices in other countries. A patient deciding whether to pay out of pocket for EBO2 is relying entirely on a clinic’s own description of benefits, not on an independent regulatory review, a distinction covered in more depth in a companion guide on whether EBO2 works. Ozone therapy is not FDA-approved for any condition, full stop, and that fact does not change based on which clinic, state, or country is being discussed.

Bottom line

EBO2 is not FDA-approved, and the regulation clinics sometimes gesture past, 21 CFR 801.415, says directly that ozone has no known useful medical application [1]. Clinics can legally offer it because state medical practice law, not FDA approval, governs what a physician may do, and both the FDA and FTC have shown they will act when marketing crosses from offering a service into claiming it treats or resolves a specific disease [4][5]. No state medical board [7] and no country’s medicines regulator has approved ozone therapy as a treatment; where clinics point to international acceptance, what actually exists is a mix of practitioner associations’ own consensus documents [8], a permissive general legal principle in Germany that a national reviewer has since declined to fund [9], regional practice directives in Italy and Spain [10], and one government health system in Cuba running the therapy in its own facilities [11]. Anyone comparing options can review clinics in their area, but should not mistake being legally available for having been approved, and should feel free to ask a clinic directly which specific agency, if any, it believes has approved the treatment it is selling.